Investor lunches and networking events with ASX-listed, Pre-IPO and startup companies - matched to your investment interests and city. Open to retail and professional investors.
How it works
Tell us your city and the sectors you invest in. Takes under a minute.
We match upcoming lunches to your profile and send an invitation by email.
Meet company management over lunch - in person or online, usually at no cost.
Sectors we cover
Critical minerals for the energy shift. Fintech for global trade. Biotech for better health. Whatever matters to you - we'll prioritise the invitations you get.
Upcoming events
We launched just a few weeks ago and are progressively adding events as we grow. Help us grow by forwarding this website link to a friend.
Pitch your story directly to a curated audience of investors, in person or online.
EnquireIn conjunction with Bantry Advisors, we are pleased to invite you to a luncheon with Nova Eye Medical. Stock Ticker: EYE Market Cap: ~$38 million Last Traded Price: $0.13 Nova Eye Medical is a medical technology company that designs, develops, and commercialises advanced devices for the treatment of glaucoma. The technology is anchored by its proprietary iTrack™ canaloplasty portfolio - pioneering microcatheter innovations developed to restore natural eye outflow and preserve delicate anatomy. Think of traditional invasive glaucoma surgeries... but with a precision, surgeon-first handheld injector that leaves tissue largely untouched. Nova Eye's flagship iTrack™ Advance uses an intuitive, engineered delivery system. A compact handheld device that allows surgeons to precisely thread through Schlemm’s canal and clear blockages in real time. It has a global commercial footprint with direct sales infrastructure spanning the United States, Australia, New Zealand, and Europe. Right now, EYE has established distribution pathways serving ophthalmic surgeons across major international markets, alongside its established Molteno3® glaucoma drainage devices for complex cases. It also continues to advance the clinical pipeline for its proprietary 2RT® (Retinal Rejuvenation Therapy) laser technology targeted at intermediate age-related macular degeneration (AMD). Key clinical users and institutional partners include prominent global teaching hospitals, research networks, and specialised ophthalmic surgical centers across the US, Europe, and Asia-Pacific.
This is an Expressions of Interest for interested members. Please register if interested: Evinco Therapeutics is a Melbourne-based biotechnology company developing a first-in-class, immune-derived nasal spray therapy to treat Alzheimer’s disease and related neurological conditions. The novel therapeutic modality uses Natural Killer (NK) cell-derived extracellular vesicles (EVs) that are purified, enhanced, and freeze-dried to non-invasively modulate neuro-inflammation and potentially overcome key limitations of current costly, limited-efficacy treatments. Evinco’s platform is being developed to deliver a low-cost, non-invasive therapy, targeting a multi-billion-dollar global market. More than 19,000 Australians died from dementia, including Alzheimer’s disease in 2025, and it remains the nation's leading cause of death. Led by stem cell pioneer Prof. Alan Trounson AO, the company is seeking an initial AUD $2.6 million initial investment for establishing the proof of concept in 2026–2027. The company aims to achieve clinical readiness within approximately 18 months and expects a further AU$4 million will enable clinical trials. Evinco’s commercial potential is backed by a strategic collaboration with a global pharmaceutical partner, active interest from a leading US venture capital group to form a funding consortium post-proof-of-concept, and local Australian neurologists ready to accelerate human trials. Preclinical evaluation using a large animal model for Cognitive Dysfunction Syndrome (CDS) will assess efficacy and safety, positioning successful early clinical validation as a strong catalyst for rapid growth or strategic acquisition. For a quick overview of Evinco’s approach, please watch this short video: https://www.youtube.com/watch?v=jf-rxBJIMjU
Carbonxt makes activated carbon products in the US. The products capture mercury and other pollutants from industrial emissions and water. It has two operating plants, Black Birch (powdered activated carbon) and Albertville in Minnesota (pellets). It also owns 49.4% of the new Kentucky activated carbon plant through NewCarbon. Why now * A record year ahead. FY27 revenue guidance is at least $22.0m, up 40% on FY26 ($15.7m), with an FY27 gross margin of around 48%. * Contracted growth. WPS has lifted its order 60% on FY26 volumes, Reworld is taking 25% more PAC from 1 January 2027, and there is a new steel industry pellet customer. * Capacity to deliver. A new mill at Black Birch will take PAC capacity to around 12,000 tons, and the Minnesota pellet plant has moved to a larger site. * Kentucky is close. The final kiln parts arrived on site in late October and testing is underway. Investors can watch for that catalyst. * Under the radar. The market cap is around $27m. The quarterly was hit by the plant move, and the share price hasn't caught up with the contracts. That gap is the opportunity.
This is an Expressions of Interest. If interested in attending, please register: Special note from Chairman, Stu Crow: By way of a brief update, you may be aware that we recently received our final key permit from the Catamarca Ministry of Mining. This places our project among a very select group of large-scale global lithium assets positioned between full permitting and Final Investment Decision (FID). At current market pricing, the company trades at approximately 3% of project NPV - a valuation gap that represents an exceptional entry point and compelling upside as we de-risk toward production. ~~~ Lake Resources NL (ASX: LKE) is an Australian clean lithium developer focused on supplying high-purity, battery-grade lithium carbonate to the global energy transition market. The company’s flagship asset is the Kachi Lithium Brine Project, located in the Catamarca Province of Argentina - a key region within the renowned "Lithium Triangle". A central pillar of Lake’s operational thesis has been the adoption of Direct Lithium Extraction (DLE) technology, developed in partnership with US-based Lilac Solutions. DLE is designed to process brine with a significantly smaller environmental footprint, lower water consumption, and faster production cycles compared to traditional evaporation ponds. In recent years, Lake Resources has navigated a transition from a high-flying speculative developer to a more restructured, cost-disciplined phase. After historical timeline shifts, board changes, and broader macro headwinds across the global lithium sector, the company reset its strategy to focus heavily on capital preservation, strategic equity partnerships, and project de-risking. A major operational milestone was achieved with the receipt of the Environmental Impact Declaration (DIA) from the Catamarca Ministry of Mining, securing the key regulatory permit required to progress Kachi into Front-End Engineering Design (FEED) for a targeted 25,000 tonnes per annum (tpa) Phase One operation. The company continues to pursue project financing, off-take agreements, and potential strategic partners to achieve a Final Investment Decision (FID).
Join the mailing list to be notified as soon as new lunches go live.
Join the listCurious who’s presented before? See past events
Gauging investor interest
Register your interest in a company - when enough investors ask, we invite it to present.
How we host
Invite-only lunches at restaurants and private function rooms in your capital city. Small groups, direct access to company management, real conversation after the presentation.
Bring investors from every city into one room. A Perth-based company can reach east coast investors without booking a multi-city roadshow. At the host's discretion, we'll send an Uber Eats voucher as a thank-you for tuning in.
Selected lunches are recorded and made available to registered investors online, so missing the date doesn't mean missing the opportunity. Availability varies by event - your invitation will note if a replay is offered.
FAQs
Looking to organise a multi-city capital raise or IPO roadshow instead? See Investor Roadshows.
